KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Assets: 2018-2025

Historic Assets for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $641.9 million.

  • Twist Bioscience's Assets rose 4.48% to $641.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $641.9 million, marking a year-over-year increase of 4.48%. This contributed to the annual value of $641.9 million for FY2025, which is 4.48% up from last year.
  • As of Q3 2025, Twist Bioscience's Assets stood at $641.9 million, which was down 0.27% from $643.6 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Assets registered a high of $1.0 billion during Q1 2022, and its lowest value of $595.6 million during Q1 2025.
  • Its 3-year average for Assets is $692.6 million, with a median of $643.6 million in 2025.
  • In the last 5 years, Twist Bioscience's Assets surged by 109.12% in 2021 and then dropped by 21.25% in 2024.
  • Over the past 5 years, Twist Bioscience's Assets (Quarterly) stood at $786.2 million in 2021, then grew by 15.75% to $910.0 million in 2022, then dropped by 19.47% to $732.8 million in 2023, then dropped by 16.95% to $608.6 million in 2024, then grew by 4.48% to $641.9 million in 2025.
  • Its Assets was $641.9 million in Q3 2025, compared to $643.6 million in Q2 2025 and $595.6 million in Q1 2025.